Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1117568 in Adults With Schizophrenia
NCT05545111Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of direclidine in schizophrenia, sponsored by Neurocrine Biosciences. Started Oct 2022; status: completed.
02
Drugs
direclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05545111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545111.